Amid Growth, Reckitt To Launch Mucinex In Emerging Markets Ahead of EU
This article was originally published in The Tan Sheet
Executive Summary
Emerging markets, the key driver for Reckitt Benckiser's nearly 20% net income growth, will be crucial in the firm's launch of Mucinex decongestants outside the U.S.
You may also be interested in...
Reckitt Benckiser Revenue Grows 15% On OTCs, SSL Acquisition
Reckitt Benckiser reports net revenue up 15% in its latest earnings period on strong sales of OTC products and new business from the now fully integrated SSL International brands.
Reckitt Benckiser Revenue Grows 15% On OTCs, SSL Acquisition
Reckitt Benckiser reports net revenue up 15% in its latest earnings period on strong sales of OTC products and new business from the now fully integrated SSL International brands.
Reckitt Benckiser Revenue Grows 15% On OTCs, SSL Acquisition
Reckitt Benckiser reports net revenue up 15% in its latest earnings period on strong sales of OTC products and new business from the now fully integrated SSL International brands.